Somatuline increased progression-free survival over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors in a randomized phase III trial.
An independent data monitoring committee recommended an early stop a phase III trial of Mekinist and Tafinlar in patients with BRAF V600E or V600K mutation-positive unresectable or metastatic cutaneous melanoma, following a demonstrated overall survival benefit.
A phase III trial of trifluridine and tipiracil hydrochloride significantly improved both overall and progression-free survival in refractory metastatic colorectal cancer that had progressed after standard therapies.
ELLEN MILLER SONET was named chief strategy and alliance officer of CancerCare.
JOHN BIRKMEYER was named executive vice president for enterprise support services for the Dartmouth-Hitchcock health system.
KEVIN FITZGERALD, a Jesuit priest, Georgetown bioethicist and cancer researcher, has been appointed by Pope Francis to serve as a consultor to the Pontifical Council for Culture.
V. CRAIG JORDAN will join MD Anderson Cancer Center as a professor in Breast Medical Oncology and Molecular and Cellular Oncology. He will begin work in October.
The Department of Defense appropriations measure for the fiscal year 2015, approved by the Senate Appropriations Committee July 17, decreased overall funding for peer-reviewed cancer research programs by 4.5 percent.
Sen. Tom Harkin introduced a bill that would set NIH on a path to recoup the purchasing power it has lost since 2003, and make funding biomedical research a national priority.
More women would die from open surgery each year if the FDA decides to ban power morcellation, said Jubilee Brown, an associate professor at MD Anderson Cancer Center and a spokesperson of the American Association of Gynecologic Laparoscopists.
